Jun 2026 (Q2 FY26) — Jul 30, 2026
PTC Therapeutics Q2 FY26 — Record Revenue and Raised Guidance Driven by Strong Sephience Launch
Read the full callPTC Therapeutics (PTCT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
PTC Therapeutics earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 361 | +101.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 41.3 | +60.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 83.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
14 of 15 judged targets kept · 6 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| MSH3 splicing program development candidate election | Elect development candidate in 2026 | Dec 2025 | We recently selected a development candidate for our MSH3 splicing program, PTC303. | Achieved |
| FY2026 product revenue guidance | $700 million to $800 million | Dec 2025 | we are raising our full year 2026 product revenue guidance to $850 million to $950 million and now expect total revenue of $1.18 billion to $1.28 billion | Revised Up |
| Vatiquinone PROVE-FA open-label study initiation | Initiate within the next few months (later specified as the third quarter of 2026) | Mar 2026 | We plan to initiate this study, PROVE-FA, in the third quarter of this year. | On Track |
1 of PTC THERAPEUTICS, INC.'s 21 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 18 more targets are in the full ledger.
Claimed
- Achieved record total revenue of $361 million, including $239 million in product revenue, representing over 100% YoY growth.
- Raised full-year 2026 product revenue guidance to $850 million-$950 million and total revenue guidance to $1.18 billion-$1.28 billion.
- Sephience global revenue reached $151 million, growing 21% QoQ, with 1,647 commercial patients globally and 100% penetration in US centers of excellence.
- Votoplam's PIVOT-HD study showed positive 24-month interim results with a 52% slowing of disease progression in the 10mg Stage 2 cohort.
- Maintained a strong cash position of $2.23 billion as of June 30, 2026, following a successful convertible note refinancing.
Qualified
- DMD franchise (Translarna and Emflaza) continues to face headwinds from generic pressure and challenges in key international markets.
- Sephience discontinuation rate remains at approximately 20%, though management views this as impressive given early patient profiles.
Price
$60.99 +2.21% · +$1.32
Performance −7.7% 1Y
1Y: $66.09 on 14 Oct 2025 → $60.99. High $89.55 (9 Jul 2026), low $59.67 (14 Oct 2026).
- Previous close
- $59.67
- 52-week range
- $59.67 – $89.55
- One year
- −10.98%
Overview
- Symbol
- PTCT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
14 of 15 judged targets kept · 6 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| MSH3 splicing program development candidate election | Elect development candidate in 2026 | Dec 2025 | We recently selected a development candidate for our MSH3 splicing program, PTC303. | Achieved |
| FY2026 product revenue guidance | $700 million to $800 million | Dec 2025 | we are raising our full year 2026 product revenue guidance to $850 million to $950 million and now expect total revenue of $1.18 billion to $1.28 billion | Revised Up |
| Vatiquinone PROVE-FA open-label study initiation | Initiate within the next few months (later specified as the third quarter of 2026) | Mar 2026 | We plan to initiate this study, PROVE-FA, in the third quarter of this year. | On Track |
Claimed
- Achieved record total revenue of $361 million, including $239 million in product revenue, representing over 100% YoY growth.
- Raised full-year 2026 product revenue guidance to $850 million-$950 million and total revenue guidance to $1.18 billion-$1.28 billion.
- Sephience global revenue reached $151 million, growing 21% QoQ, with 1,647 commercial patients globally and 100% penetration in US centers of excellence.
- Votoplam's PIVOT-HD study showed positive 24-month interim results with a 52% slowing of disease progression in the 10mg Stage 2 cohort.
- Maintained a strong cash position of $2.23 billion as of June 30, 2026, following a successful convertible note refinancing.
Qualified
- DMD franchise (Translarna and Emflaza) continues to face headwinds from generic pressure and challenges in key international markets.
- Sephience discontinuation rate remains at approximately 20%, though management views this as impressive given early patient profiles.
The full ledger
Open PTC THERAPEUTICS, INC.’s full ledger
A free account opens 5 company ledgers a month. All 21 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
PTC Therapeutics Q1 FY26 — Record Revenue and Raised Guidance Driven by Sephience Launch
Read the full callEvery analysed call
PTC Therapeutics earnings calls (PTCT)
Financials
What the filings say
Net profit, year on year: +229% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 197 | 213 | 1,176 | 179 | 211 | 165 | 273 | 361 |
| Operating profit | -55 | -162 | 970 | -35 | 3 | -71 | 45 | 149 |
| Operating margin | −27.7% | −76.2% | 82.5% | −19.5% | 1.4% | −43.3% | 16.5% | 41.3% |
| Profit before tax | -98 | -95 | 930 | -71 | -23 | -139 | -2 | 98 |
| Tax rate | −8.8% | 30.4% | 6.8% | 8.7% | 168.9% | 3.0% | −14.1% | 14.4% |
| Net profit | -107 | -66 | 867 | -65 | 16 | -135 | -3 | 83 |
| EPS ($ per share) | -1.39 | — | 11.09 | -0.83 | 0.20 | — | -0.03 | 1.01 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -939 | -1,190 | -1,629 | -2,098 | -2,657 | -3,284 | -3,647 | -2,964 |
| Total liabilities | 768 | 1,029 | 1,726 | 1,937 | 2,053 | 2,714 | 2,803 | 3,104 |
| Fixed assets | 13 | 22 | 34 | 53 | 73 | 87 | 61 | 55 |
| Investments | 58 | 399 | 895 | 584 | 131 | 283 | 360 | 961 |
| Total assets | 1,119 | 1,624 | 2,208 | 1,938 | 1,706 | 1,896 | 1,705 | 2,899 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -28 | -99 | -194 | -251 | -357 | -158 | -108 | 711 |
| Cash from investing | -43 | -387 | -562 | 219 | 290 | -177 | 44 | -862 |
| Cash from financing | 132 | 613 | 669 | 21 | 168 | 646 | 256 | 331 |
| Net cash flow | 58 | 126 | -79 | -19 | 99 | 314 | 185 | 203 |
| Capital expenditure | -7 | -14 | -18 | -28 | -32 | -28 | -7 | -9 |
| Free cash flow | -35 | -112 | -212 | -280 | -389 | -187 | -114 | 702 |
PTCT revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Life Science | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +101.5% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
PTCT operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Patients Commercial | 1,244As of March 31, we had 1,244 commercial patients globally.Source: earnings call transcript | 1,647And as of June 30, we had 1,647 commercial patients on Sephience globally.Source: earnings call transcript | +32.4% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- Non Us 48% ↓ 31 pt
- US 42% ↓ 11 pt
- All Other Countries Other Than Russia Brazil and United States 15%
- BR 7% ↓ 8 pt
- RU 2%
As PTCT cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
296 filings between Oct 30, 2025 and Oct 9, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$57.71M
204 sales by 13 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 24
- Award — granted as compensation
- 67
- Option exercise — converted options into shares
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Almstead Neil Gregory | — | $22.36M | Jul 9, 2026 |
| Pauwels Eric | — | $7.48M | Jun 10, 2026 |
| SCHMERTZLER MICHAEL | — | $6.47M | Oct 7, 2026 |
| Boulding Mark Elliott | — | $4.25M | Oct 9, 2026 |
| Klein Matthew B. | — | $4.22M | Aug 4, 2026 |
| Reeve Emma | — | $2.54M | Jan 5, 2026 |
| Jacobson Allan Steven | — | $2.13M | Nov 25, 2025 |
| Utter Christine Marie | — | $1.94M | Jun 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 plan | 192 | $7.6K |
| Oct 9, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 plan | 192 | $12.3K |
| Oct 7, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 2,447 | $155.1K |
| Oct 7, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 53 | $3.4K |
| Oct 6, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 plan | 435 | $27.9K |
| Oct 6, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 plan | 435 | $17.1K |
| Oct 5, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 plan | 1,638 | $104.9K |
| Oct 5, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 plan | 1,638 | $64.6K |
| Sep 30, 2026 | STEELE GLENN JR MD PHD Director | Sale 10b5-1 plan | 12,000 | $781.9K |
| Sep 30, 2026 | STEELE GLENN JR MD PHD Director | Option exercise 10b5-1 plan | 12,000 | $134.8K |
| Sep 17, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 9,624 | $652.8K |
| Sep 17, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 376 | $25.7K |
| Sep 16, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 7,006 | $471.9K |
| Sep 16, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 2,994 | $199.3K |
| Sep 10, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 10,000 | $673.4K |
| Sep 9, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 572 | $39.3K |
| Sep 9, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 9,428 | $639.1K |
| Aug 27, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 11,890 | $850.7K |
| Aug 27, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 610 | $44.1K |
| Aug 26, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 5,626 | $411.7K |
| Aug 26, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 6,874 | $500.0K |
| Aug 20, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 9,419 | $666.7K |
| Aug 20, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 691 | $50.4K |
| Aug 20, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 2,390 | $171.8K |
| Aug 19, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 5,335 | $388.7K |
| Aug 19, 2026 | SCHMERTZLER MICHAEL Director | Sale 10b5-1 plan | 7,165 | $527.8K |
| Aug 17, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 plan | 2,813 | $72.3K |
| Aug 17, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 plan | 969 | $70.6K |
| Aug 17, 2026 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 plan | 1,844 | $133.5K |
| Aug 4, 2026 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 10,292 | $705.7K |
| Jul 28, 2026 | Sollie-Zetlmayer Hege Elisabeth Director | Award | 2,000 | $0 |
| Jul 28, 2026 | Sollie-Zetlmayer Hege Elisabeth Director | Award | 4,000 | $0 |
| Jul 14, 2026 | Gravier Pierre CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 3,494 | $280.7K |
| Jul 9, 2026 | Smith Mary L. Director | Option exercise 10b5-1 plan | 5,834 | $250.6K |
| Jul 9, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 2,464 | $222.4K |
| Jul 9, 2026 | Smith Mary L. Director | Sale 10b5-1 plan | 5,834 | $525.1K |
| Jul 9, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise 10b5-1 plan | 2,464 | $114.7K |
| Jul 9, 2026 | Smith Mary L. Director | Sale 10b5-1 plan | 10,000 | $900.0K |
| Jul 9, 2026 | Smith Mary L. Director | Option exercise 10b5-1 plan | 10,000 | $429.5K |
| Jul 7, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 3,956 | $344.8K |
| Jul 7, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise 10b5-1 plan | 24,613 | $970.2K |
| Jul 7, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 9,288 | $830.7K |
| Jul 7, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 11,369 | $1.01M |
| Jul 6, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 2,474 | $215.3K |
| Jul 6, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise 10b5-1 plan | 2,474 | $97.5K |
| Jul 6, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 10,090 | $871.0K |
| Jul 6, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 8,786 | $749.9K |
| Jul 6, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 385 | $33.2K |
| Jul 6, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise 10b5-1 plan | 18,876 | $719.2K |
| Jul 6, 2026 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 plan | 426 | $36.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PTC THERAPEUTICS, INC.
Free account. Everything above stays public.
Write why you follow PTC THERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading